Drawing on 16‑year accumulation in innovative drug R&D, the Company has built a tiered product pipeline centered on differentiated strategies of overcoming resistance, tackling drug resistance and enhancing target selectivity, with sharp focus on unmet clinical needs. At present, the Company’s pipeline comprises one marketed drug, three clinical‑stage candidates and multiple pre‑clinical candidates spanning from R&D to marketing authorization at home and abroad, covering three major therapeutic areas: autoimmunity and inflammation, cardio‑renal metabolism, and oncology. Going forward, the Company will further expand its global footprint for new medicines. Guided by differentiated innovation philosophy, it will continuously optimize the efficacy, safety and target selectivity of innovative drugs to precisely address real‑world clinical requirements and accelerate the upgrading and iteration of drugs and clinical therapies in relevant therapeutic fields.

The R&D team keeps strengthening its professional capabilities in chemistry and pharmaceutics, and has accumulated extensive end‑to‑end drug‑development experience. To empower and reinforce in‑house innovative drug R&D, the Company leverages its proprietary high‑end technology platforms including flow chemistry, multi‑chiral technology and biocatalytic enzyme catalysis to provide integrated drug R&D and manufacturing services. It has established a one‑stop production, supply and service platform capable of delivering full‑chain solutions for clients. This business segment is independently operated by its wholly‑owned subsidiary, Nanjing Vcare BioPharma Co., Ltd. The business maintains sound development momentum and effectively fuels the Company’s innovative‑drug R&D operations.

Benefiting from its distinct differentiated strengths in innovative drugs, the Company has gained high recognition from the capital market. It has completed multiple financing rounds with total proceeds exceeding RMB 1.1 billion. In 2025, the Company was accredited as a national‑level Key Specialized, Refined, Differential & Innovative “Little Giant” Enterprise and selected for the 2025 projects under the National Science and Technology Major Project for Prevention and Treatment of Cancer, Cardiovascular‑Cerebrovascular, Respiratory and Metabolic Diseases. It has been approved to set up the Jiangsu Engineering Research Center for Small‑Molecule Innovative Pharmaceuticals, Jiangsu Provincial Enterprise Academician Workstation, Nanjing Post‑doctoral Innovation and Practice Base, and China Pharmaceutical University Enterprise Graduate Workstation. It has also been shortlisted for the Nanjing Unicorn‑to‑Be Cultivation Enterprise Directory and Nanjing Leading Innovative Enterprise Cultivation Pool. Sumecigrel, its flagship innovative drug, has received funding support from the 12th Five‑Year Plan and 13th Five‑Year Plan National Science and Technology Major Projects, winning high‑level recognition and attention from government authorities at all levels.

Looking ahead, the Company will stay true to its founding mission “The Better Care, The Better Medicines”. Centered on innovative‑drug R&D, it will keep incubating more Class‑1 innovative drug candidates that resolve clinical demands via differentiated approaches. Through pharmaceutical innovation, it safeguards public health and strives toward its corporate vision: “Innovation for a Healthier Future”.